Alpine Immune Sciences (NASDAQ:ALPN) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.31), Zacks reports. Alpine Immune Sciences had a negative net margin of 1,602.19% and a negative return on equity of 26.00%.
Shares of NASDAQ:ALPN traded up $0.03 during trading on Friday, reaching $4.84. The stock had a trading volume of 9,808 shares, compared to its average volume of 15,525. The company has a debt-to-equity ratio of 0.05, a current ratio of 20.99 and a quick ratio of 20.99. The firm has a market cap of $65.91 million, a PE ratio of -4.03 and a beta of 0.94. Alpine Immune Sciences has a fifty-two week low of $4.61 and a fifty-two week high of $11.75.
A number of equities analysts have recently weighed in on ALPN shares. Zacks Investment Research raised shares of Alpine Immune Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, July 25th. ValuEngine raised shares of Alpine Immune Sciences from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 26th. Raymond James started coverage on shares of Alpine Immune Sciences in a research report on Monday, August 13th. They issued a “buy” rating and a $13.00 price objective for the company. Finally, Piper Jaffray Companies started coverage on shares of Alpine Immune Sciences in a research report on Thursday, September 27th. They issued an “overweight” rating and a $12.00 price objective for the company. Two analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $12.67.
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.
See Also: Price to Earnings Ratio (PE) Basics
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.